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Abstract
Introduction: Tyrosine kinases are key mediators of multiple signaling pathways implicated in rheumatoid arthritis
(RA). We previously demonstrated that imatinib mesylate–a Food and Drug Administration (FDA)-approved,
antineoplastic drug that potently inhibits the tyrosine kinases Abl, c-Kit, platelet-derived growth factor receptor
(PDGFR), and c-Fms–ameliorates murine autoimmune arthritis. However, which of the imatinib-targeted kinases is
the principal culprit in disease pathogenesis remains unknown. Here we examine the role of c-Fms in autoimmune
arthritis.
Methods: We tested the therapeutic efficacy of orally administered imatinib or GW2580, a small molecule that
specifically inhibits c-Fms, in three mouse models of RA: collagen-induced arthritis (CIA), anti-collagen antibody-
induced arthritis (CAIA), and K/BxN serum transfer-induced arthritis (K/BxN). Efficacy was evaluated by visual scoring
of arthritis severity, paw thickness measurements, and histological analysis. We assessed the in vivo effects of
imatinib and GW2580 on macrophage infiltration of synovial joints in CIA, and their in vitro effects on macrophage
and osteoclast differentiation, and on osteoclast-mediated bone resorption. Further, we determined the effects of
imatinib and GW2580 on the ability of macrophage colony-stimulating factor (M-CSF; the ligand for c-Fms) to
prime bone marrow-derived macrophages to produce tumor necrosis factor (TNF) upon subsequent Fc receptor
ligation. Finally, we measured M-CSF levels in synovial fluid from patients with RA, osteoarthritis (OA), or psoriatic
arthritis (PsA), and levels of total and phosphorylated c-Fms in synovial tissue from patients with RA.
Results: GW2580 was as efficacious as imatinib in reducing arthritis severity in CIA, CAIA, and K/BxN models of RA.
Specific inhibition of c-Fms abrogated (i) infiltration of macrophages into synovial joints of arthritic mice; (ii)
differentiation of monocytes into macrophages and osteoclasts; (iii) osteoclast-mediated bone resorption; and (iv)
priming of macrophages to produce TNF upon Fc receptor stimulation, an important trigger of synovitis in RA.
Expression and activation of c-Fms in RA synovium were high, and levels of M-CSF were higher in RA synovial fluid
than in OA or PsA synovial fluid.
Conclusions: These results suggest that c-Fms plays a central role in the pathogenesis of RA by mediating the
differentiation and priming of monocyte lineage cells. Therapeutic targeting of c-Fms could provide benefit in RA.
Introduction
Rheumatoid arthritis (RA) is an autoimmune synovitis
that affects 0.6% of the world population [1]. RA is char-
acterized by inflammation and pannus formation in the
synovial joints and by periarticular erosions, biomecha-
nical dysfunction, and early mortality. Although the
advent of biological therapeutics has revolutionized the
treatment of RA, a significant number of patients with
RA do not respond well to therapy. The current genera-
tion of biologic agents either blocks a critical cytokine,
such as tumor necrosis factor (TNF) [2], or targets cells
of the adaptive immune system, such as B [3] and T [4]
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may also contribute to the pathogenesis of RA [1].
While adaptive autoimmune responses directed against
synovial joint antigens are likely involved in the early
stages of RA, widespread dysregulation of non-antigen-
specific cellular responses–including aggressive growth
of fibroblast-like synoviocytes (FLSs), proinflammatory
cytokine production by macrophages, and activation of
osteoclasts–likely underlies the chronic inflammatory
stage of RA. Elucidation of the cellular responses that
are central to the pathogenesis of RA could lead to the
development of novel targeted therapies.
Imatinib mesylate (imatinib) is a tyrosine kinase inhi-
bitor approved for the treatment of Bcr-Abl-expressing
chronic myelogenous leukemias and c-Kit-expressing
gastrointestinal stromal tumors [5,6]. Recent case
reports describe the alleviation of RA symptoms in RA
patients receiving imatinib for the treatment of these
cancers [7-9], suggesting that tyrosine kinases are
important in the pathogenesis of RA. Indeed, we and
others have shown that imatinib ameliorates autoim-
mune arthritis in animal models of RA [10-12]. At
micromolar concentrations, imatinib inhibits a narrow
spectrum of tyrosine kinases, including c-Kit, platelet-
derived growth factor receptor (PDGFR) a/b,A b l ,
Abl-related kinases, and c-Fms (also known as colony-
stimulating factor receptor 1) [13-15]. We previously
demonstrated that micromolar concentrations of imati-
nib abrogated multiple pathways implicated in RA
pathogenesis, including production of proinflammatory
cytokines by synovial macrophages, proliferation of
FLSs, production of TNF by mast cells, and proliferation
of, and antibody production by, B cells [12]. These
effects were associated with inhibition of c-Fms activa-
tion in synovial macrophages, of PDGFR activation in
FLSs, and of c-Kit activation in mast cells. Still unknown
are the relative contribution of these kinases and their
associated cellular responses to the pathogenesis of RA.
Elucidation of the kinases central to pathogenesis would
enable the development of highly specific inhibitors with
an improved therapeutic index for the treatment of RA.
Accumulating evidence underscores the importance of
monocyte lineage cells in the chronic inflammatory
stage of RA. Upon migration to tissues, monocytes dif-
ferentiate into macrophages and osteoclasts, which per-
form several homeostatic functions [16,17]. In addition
to their role in immune defense, macrophages clear cell
debris and participate in tissue remodeling following an
inflammatory response. Osteoclasts play a key role in
bone remodeling by resorbing bone, and under physio-
logical conditions, their activity is tightly coordinated
with that of osteoblasts, which are responsible for form-
ing bone [18]. In RA, monocyte lineage cells are aber-
rantly activated: an increase in macrophage infiltration
of the synovium promotes inflammation via the produc-
tion of TNF and other proinflammatory cytokines, and
an increase in osteoclast activity promotes erosion of
bone [19].
Development and proliferation of monocyte lineage
cells are mediated by c-Fms [17], a member of the
PDGFR family of tyrosine kinases. The c-Fms ligand
macrophage colony-stimulating factor (M-CSF) is pro-
duced predominantly by FLSs, T cells, and endothelial
cells, and its expression is upregulated in these cells in
RA [20,21]. Recently, interleukin-34 (IL-34) was identi-
fied as a second ligand for c-Fms [22]. Although c-Fms
has been implicated in RA, prior studies have not fully
defined the cellular mechanisms by which c-Fms modu-
lates autoimmune arthritis. Here, we dissect the role of
c-Fms, demonstrating that c-Fms signaling promotes the
formation and activation of macrophages and osteo-
clasts. These findings reveal the relevance of c-Fms to
specific cellular processes important in the pathogenesis
of RA. Furthermore, we demonstrate that a specific
small-molecule inhibitor of c-Fms is effective in treating
arthritis in multiple mouse models of RA.
Materials and methods
Small-molecule inhibitors and antibodies
In the in vitro studies, we used imatinib mesylate that
was chemically synthesized and confirmed to be more
than 98% pure by the Organic Synthesis Core Facility at
Memorial Sloan-Kettering Cancer Center (New York,
NY, USA). In the in vivo studies, we used imatinib
mesylate tablets (Stanford Inpatient Pharmacy Services,
Palo Alto, CA, USA), which were ground and resus-
pended in the vehicle. GW2580 provided by GlaxoS-
mithKline (Uxbridge, Middlesex, UK) was used in the
studies on prevention of arthritis (Figures 1 and 2).
GW2580 purchased from Calbiochem (San Diego, CA,
USA) and GW2580 chemically synthesized and con-
firmed to be more than 99% pure by SRI International
(Menlo Park, CA, USA) were used in the studies on the
treatment of arthritis (Figures 1 and 2), the experiments
shown in Figures 3, 4, 5 and 6, and the experiments
shown in Additional file 1. Anti-c-Fms, anti-phospho-c-
Fms, and isotype control antibodies were from Santa
Cruz Biotechnology, Inc. (Santa Cruz, CA, USA).
IC50 determination
c-Kit and Abl kinase activity in the presence or absence
of small-molecule inhibitors was determined by using
HTScan kinase assay kits (Cell Signaling Technology,
Inc., Danvers, MA, USA) coupled with europium-
labeled DELFIA assays (PerkinElmer, Waltham, MA,
USA), and counts were measured by time-resolved
fluorescence (PerkinElmer) in accordance with the pro-
tocols of the manufacturer. To assess c-Fms activity, we
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Page 2 of 15Figure 1 c-Fms inhibition prevents and treats autoimmune arthritis. Clinical arthritis scores (left panels) and paw thickness measurements
(right panels) of arthritic mice treated with imatinib or GW2580. (a, b) Collagen-induced arthritis (CIA) prevention studies in DBA/1 mice;
administration of vehicle (n = 12), 30 mg/kg GW2580 (n = 12), 80 mg/kg GW2580 (n = 12), or 80 mg/kg imatinib (n = 12) started 1 day before
induction of CIA. (c, d) CIA treatment studies in DBA/1 mice; administration of vehicle (n = 15), 80 mg/kg GW2580 (n = 15), or 80 mg/kg
imatinib (n = 15) started once CIA is established as indicated. (e, f) Anti-collagen antibody-induced arthritis (CAIA) prevention studies in BALB/c
mice; administration of vehicle (n = 5), 80 mg/kg GW2580 (n = 5), or 80 mg/kg imatinib (n = 5) started 1 day before transfer of anti-collagen
type II antibodies. (g, h) K/BxN prevention studies in BALB/c mice; administration of vehicle (n = 5), 80 mg/kg GW2580 (n = 5), or 80 mg/kg
imatinib (n = 5) started 1 day before transfer of K/BxN serum. The data shown in (a-h) are representative of three independent experiments.
Values are the mean ± standard error of the mean for the representative experiment shown. *P < 0.05, **P < 0.01 compared with vehicle-treated
mice.
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Page 3 of 15Figure 2 c-Fms inhibition reduces synovitis, pannus formation, and joint erosion in autoimmune arthritis. (a) Representative Toluidine
blue-stained joint sections from DBA/1 mice in the collagen-induced arthritis (CIA) prevention study. Images are shown at × 100 magnification
and are representative of at least two independent experiments. Histopathologic scores for synovitis, pannus formation, and joint erosion in (b)
DBA/1 mice with CIA in the prevention study (vehicle, n = 10; 80 mg/kg GW2580, n = 10; 80 mg/kg imatinib, n = 10), (c) DBA/1 mice with CIA
in the treatment study (vehicle, n = 8; 80 mg/kg GW2580, n = 8; 80 mg/kg imatinib, n = 8), (d) BALB/c mice with anti-collagen antibody-
induced arthritis (CAIA) (vehicle, n = 5; 80 mg/kg GW2580, n = 5; 80 mg/kg imatinib, n = 5), and (e) BALB/c mice with K/BxN serum transfer
arthritis (vehicle, n = 5; 80 mg/kg GW2580, n = 5; 80 mg/kg imatinib, n = 5). The data shown are representative of at least two independent
experiments. Values are the mean ± standard error of the mean. *P < 0.05 compared with vehicle-treated mice.
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Page 4 of 15Figure 3 c-Fms inhibition blocks macrophage differentiation and joint infiltration. (a) Representative immunohistochemistry images of
sections of ankle joint tissue from DBA/1 mice treated with vehicle, GW2580, or imatinib in a collagen-induced arthritis prevention study. Joint
sections were stained with antibodies against total c-Fms, the macrophage marker F4/80, or antibody isotype controls. Images are shown at ×
400 magnification and are representative of at least three independent experiments. (b, c) Differentiation to macrophages. Bone marrow cells
from naïve BALB/c mice were treated with macrophage colony-stimulating factor (M-CSF) alone for 5 days to promote monocyte maturation
and then incubated with (+) or without (-) M-CSF for an additional 48 hours in the presence of GW2580 or imatinib, as indicated. (b)
Representative inverted microscopic images of untreated monocytes (left panel) and M-CSF-treated monocytes ± GW2580 or imatinib. (c) The
percentage of macrophages in untreated or M-CSF-treated cultures in the presence of 0 to 10 μM GW2580 or imatinib was determined with an
assay that detects a-naphtyl acetate esterase activity, coupled with fluoride inhibition. **P < 0.01.
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Page 5 of 15incubated human peripheral blood mononuclear cells
with 20 ng/mL M-CSF in the presence or absence of
small-molecule inhibitors and determined the percen-
tage of macrophages, as described below. To assess
PDGFR activity, we isolated human FLSs as previously
described [12], stimulated them for 72 hours with 20
ng/mL PDGF-bb in the presence of small-molecule
inhibitors, pulsed them with 1 μCi [
3H] thymidine (ICN
Pharmaceuticals, Costa Mesa, CA, USA) for the final 18
hours of the stimulation, and used a Betaplate scintilla-
tion counter (PerkinElmer) to quantify the radioactivity
incorporated. Scintillation counts were used to generate
nonlinear regression dose-response curves for each
small-molecule inhibitor, and IC50s (half inhibitory con-
centrations) were determined by using Prism software
(GraphPad Software, Inc., San Diego, CA, USA).
Synovial fluid and tissue samples from patients with
arthritis
Human synovial fluid and synovial tissue samples were
collected from RA, osteoarthritis (OA), and psoriatic
arthritis (PsA) patients who met the American College
of Rheumatology criteria. Samples were collected in
accordance with protocols approved by the Stanford
University Institutional Review Board after procurement
of informed consent.
Models of autoimmune arthritis
Six- to eight-week-old male DBA/1 mice and female
BALB/c mice were purchased from The Jackson Labora-
tory (Bar Harbor, ME, USA) and housed at Stanford
University under protocols approved by the Stanford
University Committee of Animal Research and in
Figure 4 c-Fms inhibition blocks osteoclast differentiation. Bone marrow cells from naïve BALB/c mice were treated with macrophage
colony-stimulating factor (M-CSF) alone for 24 hours and then transferred to plates with either dentine disks (a, b) or osteologic disks (c) and
treated with M-CSF and receptor activator of nuclear factor-kappa B ligand (RANKL) ± GW2580 or imatinib. (a) Representative images showing
reduction in tartrate-resistant acid phosphatase-positive (TRAP
+) cell numbers following treatment with imatinib or GW2580. For quantification,
the dentine disk area that stained positive for TRAP
+ multinucleated cells (b) and the degree of pit formation in osteologic disks (c) are
expressed as a percentage of the area stained or of the pit formation detected following treatment with M-CSF and RANKL. The data shown are
representative of at least two independent experiments. Values are the mean ± standard error of the mean. **P < 0.01 compared with cells
treated with M-CSF and RANKL alone (b, c).
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Page 6 of 15Figure 5 c-Fms signaling primes macrophage response to lipopolysaccharide (LPS) or immune complex stimulation. Fully differentiated,
bone marrow-derived macrophages pretreated with macrophage colony-stimulating factor (M-CSF) for 3 hours in the absence or presence of 5
μM GW2580 or imatinib followed by stimulation with (a) low-dose LPS (1 ng/mL) or (b) FcRgII/III cross-linking (20 μg/mL plate-bound 2.4G2
antibody). After 24 hours of culture, tumor necrosis factor (TNF) in the supernatants was measured by enzyme-linked immunosorbent assay.
Values are the mean ± standard error of the mean. **P < 0.01 compared with unprimed stimulated cells without inhibitor. Results are
representative of at least three independent experiments. IC, immune complex.
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Page 7 of 15accordance with National Institutes of Health guide-
lines. Collagen-induced arthritis (CIA) in DBA/1 mice
was induced and scored as previously described [23].
Briefly, DBA/1 mice were immunized by intradermal
injection of 100 μg/mouse bovine collagen type II (CII)
(Chondrex, Inc., Redmond, WA, USA) emulsified in
complete Freund’s adjuvant (CFA) containing 250 μg/
mouse heat-killed Mycobacterium tuberculosis H37Ra
(Becton, Dickinson and Company, Franklin Lakes, NJ,
USA). Twenty-one days after immunization, mice were
given a subcutaneous boost injection (at the base of the
tail) of 100 μg/mouse bovine CII emulsified in incom-
plete Freund’s adjuvant (IFA). In BALB/c mice, anti-col-
lagen antibody-induced arthritis (CAIA) was induced by
intravenous injection of 1 mg of Arthrogen monoclonal
antibody blend (Chondrex, Inc.) followed by 25 μgo f
lipopolysaccharide (LPS) (Chondrex, Inc.) 3 days later.
K/BxN arthritis was induced in BALB/c mice by intra-
peritoneal (i.p.) injection of 1 μL of K/BxN serum per 1
g of mouse weight, followed 48 hours later by i.p. injec-
tion of 0.5 μLo fK / B x Ns e r u mp e r1go fm o u s e
weight. Arthritis severity was evaluated according to the
following visual scoring system: 0 = no swelling or
erythema; 1 = mild swelling and erythema of digits or
paw; 2 = moderate swelling and erythema confined to
the area distal to the mid-paw; 3 = more-pronounced
swelling and erythema extending to the ankle; 4 =
severe swelling, erythema, and joint rigidity of the ankle,
foot, and digits. Each limb was assigned a score of 0 to
4, with a maximum possible score of 16 for each
mouse. Paw thickness was determined by measuring the
thickness of both hind paws with 0- to 10-mm calipers
and calculating the mean of the two measurements.
In vivo dosing with small-molecule inhibitors
For administration in vivo, GW2580 and imatinib were
diluted in 0.5% hydroxypropylmethylcellulose and 0.05%
Tween-80 solution. GW2580 and imatinib were deliv-
ered by oral gavage twice daily at the specified doses,
starting 1 day before immunization in the CIA preven-
tion studies, following arthritis development (average
visual arthritis score of 2) in the CIA treatment studies,
a n d1d a yb e f o r ea n t i b o d yt r a n s f e ri nt h eC A I Ao rK /
BxN arthritis studies. Dosing was continued for the
duration of the experiment. Administration of vehicle
had no effect on the onset or severity of arthritis in
mice.
Histological evaluation
Hind limbs from mice with autoimmune arthritis were
fixed and decalcified in CalEx II (Fischer Scientific,
Pittsburgh, PA, USA) for 3 days before being paraffin-
Figure 6 Macrophage colony-stimulating factor (M-CSF), total c-Fms, and phospho-c-Fms are upregulated in human rheumatoid
arthritis (RA) synovium. (a) Levels of M-CSF in synovial fluid from patients with RA (n = 14), osteoarthritis (OA) (n = 15), or psoriatic arthritis
(PsA) (n = 12) were measured by Luminex bead-based arrays. Values are the mean ± standard error of the mean. **P < 0.01 compared with RA
samples. (b) Representative immunohistochemical images of RA synovium stained with antibodies against c-Fms, phospho-c-Fms, or isotype
controls.
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Page 8 of 15embedded. Histological assessment of arthritis severity
was made by blinded evaluation of Toluidine blue-
stained joint sections in accordance with a previously
described scoring system: 0 = normal; 1 = mild inflam-
mation, mild hyperplasia of the synovial lining layer,
and mild cartilage destruction without bone erosion;
2 to 4 = increasing degrees of inflammatory cell infil-
trates, synovial lining hyperplasia and pannus formation,
and cartilage and bone destruction [24].
Immunohistochemistry
Sections of paraffin-embedded synovium from RA
patients and decalcified joint tissue from mice with
autoimmune arthritis were deparaffinized, rehydrated,
and subjected to antigen retrieval as described pre-
viously [25,26].
Macrophage differentiation
Bone marrow cells were harvested from BALB/c mice
and monocyte lineage cells were generated according to
standard procedures [27]. After 4 to 5 days of culture,
bone marrow-derived monocytes were incubated for
48 hours with 20 ng/mL M-CSF (PeproTech, Rocky
Hill, NJ, USA) in the presence of 0 to 10 μM GW2580
or imatinib. To distinguish between monocytes and
macrophages, we performed an a-napthyl acetate
esterase assay, coupled with fluoride inhibition, in accor-
dance with the protocol of the manufacturer (Sigma-
Aldrich). At least 100 monocytes and macrophages were
counted in triplicate for each experimental condition,
and data are expressed as a percentage of macrophages
in culture.
Osteoclast differentiation
Twenty-four hours after their isolation from BALB/c
mice, undifferentiated bone marrow cells were trans-
ferred to dentine disks (Immunodiagnostic Systems,
Scottsdale, AZ, USA) or osteologic disks (BD Bios-
ciences, San Jose, CA, USA) and cultured for 6 days in
t h ep r e s e n c eo f5 0n g / m LM - C S Fa n d5 0n g / m Lr e c e p -
tor activator of nuclear factor-kappa-B ligand (RANKL)
(PeproTech) together with 0 to 5 μM small-molecule
inhibitor. To identify multinucleated, tartrate-resistant
acid phosphatase-positive (TRAP
+) osteoclasts, we
stained cells cultured on dentine disks with the acid
phosphatase leukocyte kit (Sigma-Aldrich). ImageJ soft-
ware was used to determine the dentine disk area that
stained positive for TRAP
+ multinucleated cells. Pit for-
mation was assessed by measuring the removal of sur-
face film on osteologic disks with the Bioquant Osteo II
image quantification system (Bioquant Image Analysis
Corporation, Nashville, TN, USA).
Macrophage priming
Bone marrow cells were harvested from BALB/c mice
and macrophages were generated as previously described
[27]. Macrophages were cultured overnight in complete
RPMI media in the absence of M-CSF and then incubated
for 3 hours in the presence of 0 to 50 ng/mL M-CSF and
0t o5μM small-molecule inhibitor, as described above.
After 3 hours, cells were stimulated with 1 ng/mL LPS
(Sigma-Aldrich) or 20 μg/mL plate-bound rat anti-mouse
2.4G2 (BD Biosciences) for 24 hours, as previously
described [28], and supernatants were harvested for cyto-
kine analysis by enzyme-linked immunosorbent assay
(ELISA).
T-cell stimulation
Splenocytes from CIA mice treated chronically with 80
mg/mL GW2580, 80 mg/mL imatinib, or vehicle were
stimulated for 72 hours with 20 μg/mL whole, dena-
tured bovine CII (Chondrex, Inc.). One microcurie of
[
3H] thymidine (ICN Pharmaceuticals) was added for
the final 18 hours of culture, and radioactivity incor-
poration was quantified by using a Betaplate scintillation
counter. Supernatants after 72 hours were harvested for
cytokine analysis by ELISA.
Statistics
Visual arthritis scores, paw thicknesses, and histology
scores were compared by the Mann-Whitney U test
with GraphPad InStat Version 3.0 (GraphPad Software,
Inc.). Differences in arthritis scores were determined by
the Fisher test with Analyse-it plug-in software (Ana-
lyse-it Software, Ltd., Leeds, UK) for Excel (Microsoft
Corporation, Redmond, WA, USA). Macrophage differ-
entiation, osteoclast differentiation, macrophage priming,
and cytokine level were compared by unpaired t tests
with GraphPad InStat Version 3.0 (GraphPad Software,
Inc.).
Results
c-Fms inhibition prevents and treats autoimmune arthritis
To determine whether specific inhibition of c-Fms pro-
vides benefit in autoimmune arthritis, we explored the
effects of GW2580 in several distinct models of RA and
compared them with the effects of imatinib. Imatinib
inhibits c-Kit, Abl, PDGFR, and c-Fms with IC50so f0 . 1 ,
0.25, 0.1, and 1.4 μM, respectively. On the basis of pub-
lished pharmacokinetic profiles [12], imatinib was admi-
nistered to mice orally, twice daily at a dose of 80 mg/kg.
GW2580 was administered to mice orally, twice daily at
d o s e so f3 0o r8 0m g / k g .P r e v i o u sp h a r m a c o k i n e t i cs t u -
dies in mice have determined that oral administration of
80 mg/kg GW2580 yields a maximal plasma concentra-
tion of 5.6 μM [29]. To determine the IC50 of GW2580
for the kinases c-Kit and Abl, we used cell-free kinase
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http://arthritis-research.com/content/12/1/R32
Page 9 of 15assays with time-resolved fluorescence. The IC50sw e r e
73.5 μM for Abl (Additional file 1a) and greater than
100 μM for c-Kit (Additional file 1b) and concentrations
significantly above the maximal plasma concentrations of
GW2580 achieved in mice receiving 80 mg/kg GW2580.
Using cell-based assays, we showed that GW2580
potently inhibits c-Fms (IC50 =0 . 0 1μM; Additional file
1c) and can inhibit PDGFR only at supraphysiological
concentrations (IC50 =1 2 . 1μM; Additional file 1d).
Thus, dosing of mice with GW2580 at a concentration of
80 mg/kg or less should inhibit c-Fms but not Abl, c-Kit,
or PDGFR. Indeed, in a cell-free assay that measures the
specificity of small-molecule inhibitors, GW2580 at 10
μM abolished c-Fms activity and did not cross-react with
nearly 200 other kinases [30].
CIA was induced by injection of DBA/1 mice with
bovine CII emulsified in CFA, followed 21 days later
by a boost injection of CII emulsified in IFA. When
imatinib dosing was initiated 1 day before the induc-
tion of CIA, it significantly reduced the severity of
arthritis (Figure 1a, b), in agreement with our previous
findings [12]. Likewise, mean arthritis scores and paw
thickness measurements were significantly lower in
mice dosed prophylactically with 30 or 80 mg/kg
GW2580 compared with mice dosed with vehicle.
GW2580 was as efficacious as imatinib in preventing
the development of arthritis. Furthermore, when the
kinase inhibitors were administered after the induction
of arthritis, both GW2580 and imatinib significantly
inhibited the progression of arthritis (Figure 1c, d).
Mice were sacrificed between days 48 and 50 as this
represents the peak of synovitis and inflammation. In
the CIA experiments presented, all mice developed
arthritis by the time the experiment was terminated
(100% incidence).
Imatinib has been shown to ameliorate CAIA [10]. We
performed experiments to determine whether specific
inhibition of c-Fms would yield a similar benefit in
CAIA. We induced CAIA by injecting BALB/c mice with
1 mg of anti-collagen antibodies, followed by 25 μgo f
LPS 3 days later. Administration of GW2580 or imatinib
was started 1 day before the transfer of antibodies. All
CAIA mice developed arthritis by day 6 after antibody
transfer (100% incidence). Arthritis was significantly less
severe in CAIA mice treated with the c-Fms-specific inhi-
bitor GW2580 compared with vehicle-treated CAIA mice
(Figure 1e, f). The course of arthritis in GW2580-treated
CAIA mice mirrored that in imatinib-treated CAIA mice.
We induced K/BxN arthritis in BALB/c mice by trans-
ferring 1 μL of serum/g of mouse weight, followed by
0.5 μL of serum/g of mouse weight 48 hours later.
Administration of GW2580 or imatinib was initiated 1
day before the transfer of serum. All K/BxN mice devel-
oped arthritis by day 4 after serum transfer (100%
incidence). Arthritis was significantly less severe in K/
BxN mice treated with GW2580 or imatinib compared
with vehicle-treated K/BxN mice (Figure 1g, h).
c-Fms inhibition reduces histopathologic severity in
autoimmune arthritis
Histological analysis was performed on hind paws har-
vested from mice treated with 80 mg/kg GW2580,
80 mg/kg imatinib, or vehicle in the studies described
above. Representative images of Toluidine blue-stained
joint tissue sections from GW2580-, imatinib-, and vehi-
cle-treated mice in the CIA prevention studies are pre-
sented (Figure 2a). Histopathologic evaluation by an
investigator blinded to treatment groups for synovitis,
formation of pannus, and erosion of cartilage and bone
in paws derived from mice in CIA prevention (Figure
2b, n = 10 mice per group, with both hind paws from
each mouse scored), CIA treatment (Figure 2c, n = 8
mice per group, with both hind paws from each mouse
scored), CAIA (Figure 2d, n = 5 mice per group, with
both hind paws for each mouse scored), and K/BxN
(Figure 2e, n = 5 mice per group, with both hind paws
of each mouse scored) studies. In contrast, these histolo-
gical indices of arthritis were significantly reduced in
paws from GW2580- or imatinib-treated mice in all
four models of autoimmune arthritis.
c-Fms inhibition does not modulate T-cell function in vivo
Because imatinib has been shown to modulate T-cell
function, we investigated whether specific inhibition of
c-Fms with GW2580 affects T-cell function. Splenocytes
harvested from CIA mice treated with 80 mg/kg
GW2580, 80 mg/kg imatinib, or vehicle in the preven-
tion studies were stimulated ex vivo with heat-denatured
whole CII, and [
3H] thymidine incorporation was used
as a surrogate marker of T-cell proliferation. Cells har-
vested from vehicle- and GW2580-treated CIA mice
proliferated extensively in response to CII, whereas cells
harvested from imatinib-treated CIA mice exhibited a
significantly reduced response (Additional file 2). In
addition, splenocytes derived from imatinib-treated CIA
mice stimulated with CII demonstrated significantly
reduced production of the proinflammatory cytokines
TNF and interferon-gamma compared with splenocytes
derived from vehicle- or GW2580-treated CIA mice.
There were no differences in IL-10 production in these
same cell populations stimulated with CII. Thus, imati-
nib modulates T-cell function in vivo, whereas GW2580
does not.
c-Fms inhibition blocks differentiation of monocyte cells
into macrophages
To determine the effects of imatinib and GW2580 on
macrophage infiltration of mouse joints, we assessed
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ker F4/80 in joint sections derived from CIA mice used
in the prevention studies. We found that joints from
CIA mice treated with vehicle exhibited marked expres-
sion of c-Fms protein, which colocalized with macro-
phages (Figure 3a). In contrast, in joints from CIA mice
treated with 80 mg/kg GW2580 or 80 mg/kg imatinib,
both c-Fms protein expression and macrophage infiltra-
tion were reduced.
To determine whether c-Fms inhibition affects the
formation of macrophages, we isolated bone marrow
cells from naïve BALB/c mice, treated them with
M-CSF for 5 days to promote the maturation of mono-
cytes, and cultured them for an additional 48 hours with
M-CSF to promote their differentiation into macro-
phages, in the presence or absence of small-molecule
inhibitors. Monocytes treated with M-CSF alone dis-
played a characteristic macrophage phenotype, including
extension of multipolar processes and presence of het-
erogeneous cytoplasmic vacuoles and inclusion bodies
(Figure 3b). In contrast, monocytes incubated with
media alone and M-CSF-stimulated monocytes treated
with 1 μM GW2580 morphologically resembled undif-
ferentiated monocytes. Treatment of monocytes with
M-CSF and 1 μM imatinib resulted in a heterogeneous
mix of cells, of which some morphologically resembled
monocytes and others resembled macrophages.
To confirm the effects of the c-Fms inhibitors on
macrophage formation, we applied an assay for the
detection of a-naphthyl acetate esterase activity, coupled
with fluoride inhibition, to the cell culture system
described above. In this assay, the granules of differen-
tiated macrophages stain, whereas monocytes remain
unstained [31]. Monocytes were generated as described
above, cultured for 48 hours with M-CSF in the pre-
sence of 0 to 10 μM GW2580 or imatinib, and then
fixed and stained for a-naphthyl acetate esterase activity.
Approximately 20% of monocytes cultured in media
alone formed macrophages; the addition of M-CSF
increased the percentage of macrophages to nearly 90%
of the total cell population (Figure 3c). Imatinib reduced
macrophage formation in a dose-dependent manner.
GW2580 suppressed macrophage formation at lower
concentrations than imatinib, in keeping with GW2580
being the more potent c-Fms inhibitor. There were no
differences in apoptosis between untreated cells and
cells treated with imatinib or GW2580 (data not shown).
c-Fms inhibition blocks the differentiation of monocytes
into osteoclasts
We performed experiments to determine whether
GW2580 could suppress the formation of osteoclasts.
Bone marrow cells were isolated from naïve BALB/c
mice, and after 24 hours in culture with M-CSF, the
suspension cells were transferred to plates containing
dentine or osteologic discs and were co-cultured with
M-CSF and RANKL in the presence or absence of
GW2580 or imatinib. Treatment with M-CSF and
RANKL led to marked formation of large TRAP
+ multi-
nucleated cells, which are indicative of osteoclasts. For
each treatment condition, the dentine disk area that
stained positive for TRAP
+ multinucleated cells was cal-
culated by ImageJ software and expressed as a percen-
tage of the area stained positive for TRAP
+ following
treatment with M-CSF and RANKL alone. Both
GW2580 and imatinib significantly reduced the forma-
tion of multinucleated TRAP
+ osteoclasts, albeit with
different potencies (inhibition achieved with 0.2 μM
GW2580 was comparable to that achieved with 1 μM
imatinib) (Figure 4a, b). Because osteoclasts erode bone
in RA joints, we next examined the formation of pits in
osteologic disks, an indication of the ability of osteo-
clasts to resorb bone. We found that treatment of cells
with imatinib (0.2 or 1 μM) resulted in a dose-depen-
dent reduction in pit formation and that treatment with
0.2 μM GW2580 blocked pit formation (Figure 4c).
c-Fms activation primes macrophage tumor necrosis
factor production in response to lipopolysaccharide or
immune complex stimulation
Whether c-Fms activation promotes anti-inflammatory
or proinflammatory activity in fully differentiated
macrophages is controversial [32,33]. To explore the
role of c-Fms in macrophage production of the proin-
flammatory cytokine TNF, we performed priming stu-
dies with fully differentiated macrophages derived from
bone marrow cells of BALB/c mice. Macrophages
primed with M-CSF for 3 hours in the presence or
absence of 5 μM GW2580 or imatinib were stimulated
with 1 ng/mL LPS for 24 hours, and TNF protein in the
cell culture supernatants was then measured by ELISA.
Cells cultured in media alone or M-CSF alone produced
very little TNF (Figure 5a). Low-dose LPS stimulated
TNF production, which was significantly increased in
macrophages primed with M-CSF for 3 hours before the
addition of LPS. GW2580 or imatinib at 5 μM (a clini-
cally relevant concentration) reduced TNF production
to levels detected in cells treated with LPS alone.
Although LPS is routinely used in experimental settings
for the stimulation of proinflammatory cytokine produc-
tion by macrophages, it is not a true trigger for the pro-
duction of TNF in RA. Important physiological triggers
of inflammation in RA are immune complexes that bind
and activate Fc receptors [34]. To examine the role of c-
Fms in TNF production elicited by immune complexes,
we used the FcR-specific anti b o d y2 . 4 G 2a sas u r r o g a t e
for immune complex-mediated Fc activation. Stimulation
of macrophages with 2.4G2 alone for 24 hours elicited a
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phages that were first primed with M-CSF for 3 hours
and then stimulated with 2.4G2 produced substantial
amounts of TNF. Co-culturing of cells with 5 μM
GW2580 or imatinib blocked the M-CSF- and 2.4G2-
induced increase in TNF production.
Levels of total c-Fms, phospho-Fms, and M-CSF in
rheumatoid arthritis patients
To demonstrate involvement of the M-CSF/c-Fms axis
in human RA, we used Luminex bead arrays to deter-
mine M-CSF protein levels in synovial fluid derived
from patients with RA, OA, or PsA. M-CSF levels were
significantly higher in human RA synovial fluid than in
OA or PsA synovial fluid (Figure 6a). We also assessed
levels of total c-Fms and phosphorylated c-Fms in
human RA synovium and found that both expression
and activation of c-Fms are high (Figure 6b).
Discussion
Imatinib studies to date have suggested that c-Fms,
PDGFR, c-Kit, and/or Abl tyrosine kinase pathways may
contribute to the pathogenesis of RA, but the dominant
pathways and cellular mechanisms involved remain
unclear [10-12]. Prior studies have not addressed the
specific cellular mechanisms by which c-Fms mediates
autoimmune arthritis. The studies provided herein sug-
gest that c-Fms-mediated differentiation and activation
of macrophages and osteoclasts play a central role in
the pathogenesis of autoimmune arthritis. Furthermore,
the c-Fms-specific inhibitor GW2580 was as efficacious
as imatinib in the treatment of autoimmune arthritis.
In an adjuvant arthritis model in rats, GW2580 sup-
pressed bone destruction but did not affect joint inflam-
mation [30]. Here, we show that GW2580 inhibits both
bone erosion and joint inflammation in multiple mouse
models of RA, indicating that c-Fms plays a critical role
in regulating inflammatory arthritis. Reported disparities
in the effects of candidate therapeutic compounds on
inflammatory arthritis may be due to differences in the
RA models used, none of which encompasses all of the
features of RA; therefore, candidate therapeutics should
ideally be tested in multiple models of RA [35]. We
investigated the effects of GW2580 in three distinct
models of RA. Induction of arthritis in the CIA model is
dependent on adaptive immune responses, whereas
i n d u c t i o ni nt h eC A I Aa n dK / B x Nm o d e l s –antibody
transfer models that bypass the requirement for T and
B cells–is dependent solely on innate immune
responses. Inhibition of c-Fms reduced arthritis severity
in both types of RA models, indicating that c-Fms is
integral to the pathogenesis of autoimmune arthritis.
Furthermore, GW2580 reduced arthritis severity when
administered either before the onset of arthritis or
following the establishment of arthritis, suggesting that
c - F m sp l a y sar o l ei nb o t ht h ee a r l ya n dt h ec h r o n i c
stages of autoimmune arthritis. Our data are consistent
with previous findings demonstrating the importance of
the c-Fms ligand M-CSF in CIA: exogenous M-CSF was
shown to exacerbate CIA, whereas a neutralizing anti-
body against M-CSF reduced arthritis severity and
M-CSF deficiency conferred resistance to CIA [36].
Recently, IL-34 was identified as a second ligand for
c-Fms [22]; the role of IL-34-mediated stimulation of
c-Fms in RA remains to be investigated.
M-CSF/c-Fms signaling drives the differentiation of
monocytes into macrophages or osteoclasts, both of
which contribute to synovial inflammation and joint
destruction in RA. Using mouse models of autoimmune
arthritis, we demonstrate that GW2580 blocks the for-
mation of macrophages and osteoclasts in vitro and
reduces macrophage infiltration of joints in vivo.
Furthermore, we demonstrate that M-CSF and both
total and activated c-Fms are highly expressed in the
synovium of RA patients. Together, our data underscore
the importance of the M-CSF/c-Fms signaling pathway
in RA pathogenesis and suggest that inhibition of c-Fms
ameliorates autoimmune arthritis by abrogating the dif-
ferentiation of monocyte lineage cells.
An increase in osteoclast numbers in RA leads to
pathogenic degradation of bone [37]. Both the M-CSF/
c-Fms and the RANKL/RANK signaling pathways are
required for formation of osteoclasts. Results from a
recent phase II trial demonstrated that blockade of
RANKL with denosumab decreased structural damage,
including bone erosions, in patients with RA; however,
it had no effect on the American College of Rheumatol-
ogy response criteria, DAS28 (disease activity score
using 28 joint counts) criteria, or RA flares [38]. Simi-
larly, preclinical studies demonstrated that RANKL inhi-
bition mitigated bone erosions without improving
clinical parameters of disease in autoimmune arthritis
[39]. Thus, in the treatment of autoimmune arthritis,
inhibiting RANKL is not as efficacious as inhibiting c-
Fms. We propose that inhibition of c-Fms is more effi-
cacious because c-Fms is crucial to the formation of
macrophages in addition to osteoclasts.
The clinical improvement following c-Fms inhibition
in our autoimmune arthritis models was rapid. Such
rapidity of the response cannot be attributed to effects
on differentiation of monocyte lineage cells, a process
that occurs over several days, nor can it be attributed to
effects on T cells as splenocytes from GW2580-treated
CIA mice exhibited activity similar to splenocytes from
vehicle-treated CIA mice. This is in contrast to results
from studies using the c-Fms inhibitor Ki20227, in
which Ki20227-mediated suppression of CIA was asso-
ciated with a reduction in splenocyte activity [40].
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factor receptor-II (VEGFR-II) in addition to c-Fms, and
its selectivity has not been extensively evaluated [41]; it
is possible that Ki20227 inhibits additional kinases that
are important in T-cell signaling. What then is the basis
for such a rapid response to c-Fms inhibition? A crucial
role for macrophages in the development of RA is the pro-
duction of TNF and other cytokines that promote inflam-
mation [1,42]. We demonstrate that c-Fms activation
primes macrophage TNF production such that macro-
phages produce much greater amounts of TNF upon Fc
receptor stimulation, an important trigger of synovitis in
RA [34]. Thus, we propose that blockade of a c-Fms-
mediated priming effect on macrophage TNF production
underlies the rapidity of the clinical response to c-Fms
inhibition.
The CAIA and K/BxN models result in the formation
of immune complexes that activate complement, result-
ing in the recruitment and activation of neutrophils and
macrophages to produce TNF and other inflammatory
mediators. As shown in Figure 5b, we demonstrate that
specific Fms inhibition potently blocks TNF release in
response to immune complexes. Thus, inhibition of
TNF production from immune complex-stimulated
macrophages by GW2580 likely represents a primary
mechanism by which Fms inhibition provides benefit in
CAIA and K/BxN arthritis.
Although our results indicate that c-Fms plays a key
role in the pathogenesis of RA, they do not preclude
contributions by other receptor tyrosine kinases. Mice
in which c-Kit signaling is impaired–owing to a loss-
of-function mutation in either the gene encoding c-Kit
o rt h eg e n ee n c o d i n gt h ec - K i tl i g a n d –are resistant to
antibody-mediated arthritis [43,44]. Indeed, masitinib, a
tyrosine kinase inhibitor that is more selective than
imatinib for c-Kit, recently demonstrated favorable
trends in an uncontrolled phase II trial [45]. However,
masitinib potently inhibits the PDGFRa/b and Lyn
kinases in addition to c-Kit, and thus the feasibility of
treating RA by selectively inhibiting c-Kit remains to
be explored. Furthermore, PDGFR signaling in FLSs
and other cell types may also contribute to the devel-
opment of autoimmune arthritis. Hyperproliferation of
FLSs, which contribute to the formation of tumor-like
pannus in RA joints, likely results in part from an
increase in PDGFR expression and activity [46]. In
addition, PDGFR signaling may promote synovitis in
RA by inducing the production of proinflammatory
cytokines by FLSs [47]. To date, however, assessment
of the importance of PDGFR in autoimmune arthritis
and RA has been hampered by the lethality of PDGFR_
or PDGFRb deficiency in mice and the lack of small-
molecule inhibitors that selectively target PDGFRa/b.
Thus, the role of PDGFR in autoimmune arthritis
awaits further clarification.
Conclusions
We show that c-Fms plays a pivotal role in autoimmune
arthritis by promoting the differentiation and priming of
monocyte lineage cells. Selective c-Fms inhibition
affords targeting of multiple pathogenic cell types and
responses in autoimmune arthritis and represents a pro-
mising approach to the treatment of RA. Clinical trials
are warranted to evaluate the efficacy and therapeutic
index of c-Fms inhibitors in RA.
Additional file 1: GW2580 potently inhibits c-Fms kinase and does not
cross-react with other imatinib-targeted kinases at clinically relevant
concentrations. (a, b) Cell-free kinase activity assay with time-resolved
fluorescent readout for determination of the IC50 of imatinib and
GW2580 for the kinases (a) Abl and (b) c-Kit. (c) Cell-based assay for
determination of the IC50 of imatinib and GW2580 for c-Fms. Human
peripheral blood mononuclear cells were treated with M-CSF in the
presence of 0-10 μM GW2580 or imatinib for 48 hours. Macrophages
were counted and values expressed relative to M-CSF treatment alone.
(d) Cell-based assay for determination of the IC50 of imatinib and
GW2580 for PDGFR. Fibroblast-like synoviocytes from a human RA
patient were incubated with PDGF-bb in the presence of 0-30 μM
GW2580 or imatinib. After 48 hours, FLS cultures were pulsed with [
3H]
thymidine for 18 hours. Values are expressed relative to PDGF-bb
treatment. Data shown in a-d are representative of at least 2
independent experiments.
Additional file 2: GW2580 does not modulate T-cell function in vivo.
Splenocytes were harvested from DBA/1 mice with CIA and treated with
GW2580, imatinib, or vehicle, and stimulated with 20 μg/ml heat-
denatured, whole CII. [
3H]thymidine incorporation was used to measure
proliferation of CII-specific T cells. IFNg,T N F a and IL-10 were measured in
culture supernatants by ELISA. Values are the mean ± SEM. *P < 0.05
compared with stimulated cells from vehicle-treated CIA mice. Results
are representative of 2 independent experiments.
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